Evidence map›Paper›PMID 30561685›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2019

Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases.

Jennifer H Olker, Joseph J Korte, Jeffrey S Denny, Phillip C Hartig, Mary C Cardon, Carsten N Knutsen, Paige M Kent, Jessica P Christensen, Sigmund J Degitz, Michael W Hornung

Open access · greenAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 76 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Technical evaluation and standardization of the human thyroid microtissue assay.Toxicological sciences : an official journal of the Society of Toxicology · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Cross-species applicability of an adverse outcome pathway network for thyroid hormone system disruption.Toxicological sciences : an official journal of the Society of Toxicology · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Jennifer H OlkerU.S. Environmental Protection Agency.
Joseph J KorteU.S. Environmental Protection Agency.
Jeffrey S DennyU.S. Environmental Protection Agency.
Phillip C HartigU.S. Environmental Protection Agency.
Mary C CardonU.S. Environmental Protection Agency.
Carsten N KnutsenMid-Continent Ecology Division, Student Services Contractor to the U.S. EPA, NHEERL, Duluth, Minnesota 55804.
Paige M KentMid-Continent Ecology Division, ORAU Student Services Contractor to the U.S. EPA, NHEERL, Duluth, Minnesota 55804.
Jessica P ChristensenMid-Continent Ecology Division, ORAU Student Services Contractor to the U.S. EPA, NHEERL, Duluth, Minnesota 55804.
Sigmund J DegitzU.S. Environmental Protection Agency.
Michael W HornungU.S. Environmental Protection Agency.
Mid-Continent University · USEnvironmental Protection Agency · USResearch Triangle Park Foundation · US

Funding

Intramural EPA EPA999999
6 · The paper itself

Abstract

Deiodinase enzymes play an essential role in converting thyroid hormones between active and inactive forms by deiodinating the pro-hormone thyroxine (T4) to the active hormone triiodothyronine (T3) and modifying T4 and T3 to inactive forms. Chemical inhibition of deiodinase activity has been identified as an important endpoint to include in screening chemicals for thyroid hormone disruption. To address the lack of data regarding chemicals that inhibit the deiodinase enzymes, we developed robust in vitro assays that utilized human deiodinase types 1, 2, and 3 and screened over 1800 unique chemicals from the U.S. EPA's ToxCast phase 1_v2, phase 2, and e1k libraries. Initial testing at a single concentration identified 411 putative deiodinase inhibitors that produced inhibition of 20% or greater in at least 1 of the 3 deiodinase assays, including chemicals that have not previously been shown to inhibit deiodinases. Of these, 228 chemicals produced enzyme inhibition of 50% or greater; these chemicals were further tested in concentration-response to determine relative potency. Comparisons across these deiodinase assays identified 81 chemicals that produced selective inhibition, with 50% inhibition or greater of only 1 of the deiodinases. This set of 3 deiodinase inhibition assays provides a significant contribution toward expanding the limited number of in vitro assays used to identify chemicals with the potential to interfere with thyroid hormone homeostasis. In addition, these results set the groundwork for development and evaluation of structure-activity relationships for deiodinase inhibition, and inform targeted selection of chemicals for further testing to identify adverse outcomes of deiodinase inhibition.

Indexed as

AdenoviridaeBiological AssayDose-Response Relationship, DrugEnzyme InhibitorsHEK293 CellsHumansInhibitory Concentration 50Iodide PeroxidaseIodidesIodothyronine Deiodinase Type IISmall Molecule LibrariesTransfectionEnzyme InhibitorsIodide PeroxidaseIodidesiodothyronine deiodinase type IIodothyronine Deiodinase Type IIiodothyronine deiodinase type IIISmall Molecule Librariesdeiodinaseendocrine disruptionprioritizationscreeningthyroid

Identifiers

PMID30561685
PMCPMC6520049
OpenAlexW2904323763

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.